Company profilePharmaceutical#33 of 1,318 in Pakistan1 DRAP alert

HIGH - Q INTERNATIONAL

Pharmaceutical company · 298 brands · 278 molecules

Ranked #11 of 137 companies in Anti-Infectives

298 registered products 79 pharmaceutical brands 278 distinct molecules 1 DRAP alert

Company overview

298
registered products
79
pharmaceutical brands
278
distinct molecules
12
therapeutic classes
1
DRAP alerts

HIGH - Q INTERNATIONAL is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 298 product registrations across 278 distinct molecules. It is the 33rd largest registrant in Pakistan by product count, and ranks 11th of 137 in Anti-Infectives. Its portfolio is concentrated in Anti-Infectives and Other Beta-Lactam, Cephalosporins & Penems. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by HIGH

296 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

179
ceilings with an approval date
5
not revised in 2+ years
2024
oldest approval year
20245
2025159
202615
Longest without revision

Top molecules by brand count

Telmisartan8 brands
Quetiapine8 brands
Ribavirin7 brands
Amlodipine5 brands
Omeprazole5 brands
Moxifloxacin5 brands
Risperidone5 brands

Therapeutic classes

Anti-Infectives · 10Other Beta-Lactam, Cephalosporins & Penems · 7Blood Glucose Lowering Drugs, Excluding Insulin · 7Gastro · 6Cardiac Care · 6Quinolone Antibacterials · 5Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 5Blood Conditions · 5Antiemetics & Antinauseants · 4Antianemic, Iron Preparations · 4Angiotensin-Ii Antagonists, Combinations · 3Diabetes · 3

Conditions treated

General Infections · 9Ulcer/Reflux/Flatulence/Acidity · 4Anaemia · 4Oral Agents · 3Hypertension · 3Pain Killers · 3Alzheimer`S · 2Non-Sedative Agents · 2High Cholestrol · 2Vomiting/Emesis · 1Blood Clot/Thrombotic Disorder · 1Cold/Cough/Flu · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official297 products · Rs 29.97 – Rs 20,591.34
DVAGO109 products · Rs 27.14 – Rs 2,832
Servaid71 products · Rs 99 – Rs 2,586.2
Median across source: Rs 310

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Cetafend Infusion (Batch # 23RC55) by M/s Friends Pharma (Pvt.
2023-12-28

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 186 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
NABIQASIM INDUSTRIES (PVT) LTD. holds 122 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
BIO LABS (PVT) LTD. holds 78 molecules not in this portfolio
AremetherArtesunateAzathioprineAzithromycin 250MgBetamethasoneBetamethasone 0.1%

Get the full profile for HIGH

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.